Vydané akcie spoločnosti Genocea Biosciences Inc
Aká je hodnota metriky Vydané akcie spoločnosti Genocea Biosciences Inc?
Hodnota metriky Vydané akcie spoločnosti Genocea Biosciences Inc je 58.784M
Aká je definícia metriky Vydané akcie?
Vydané akcie (Shares outstanding) je počet všetkých akcií spoločnosti alebo finančných aktív, ktoré boli autorizované, vydané a kúpené investormi a sú nimi vlastnené.
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
Vydané akcie spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Genocea Biosciences Inc
Čomu sa venuje spoločnosť Genocea Biosciences Inc?
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Firmy s metrikou vydané akcie podobnou spoločnosti Genocea Biosciences Inc
- Hodnota metriky Vydané akcie spoločnosti IOL Chemicals and Pharmaceuticals je 58.706M
- Hodnota metriky Vydané akcie spoločnosti IOL Chemicals and Pharmaceuticals je 58.706M
- Hodnota metriky Vydané akcie spoločnosti Invesco Asia Trust Plc je 58.707M
- Hodnota metriky Vydané akcie spoločnosti Cyon Exploration je 58.725M
- Hodnota metriky Vydané akcie spoločnosti Teleperformance SE je 58.733M
- Hodnota metriky Vydané akcie spoločnosti Clifton Mining Co je 58.771M
- Hodnota metriky Vydané akcie spoločnosti Genocea Biosciences Inc je 58.784M
- Hodnota metriky Vydané akcie spoločnosti Jiulian Resources je 58.787M
- Hodnota metriky Vydané akcie spoločnosti B.C. Power Controls je 58.800M
- Hodnota metriky Vydané akcie spoločnosti B.C. Power Controls je 58.800M
- Hodnota metriky Vydané akcie spoločnosti Iliad SA je 58.818M
- Hodnota metriky Vydané akcie spoločnosti GTT Communications Inc je 58.820M
- Hodnota metriky Vydané akcie spoločnosti California Water Service je 58.825M